Viking Therapeutics falls on third quarter loss miss
Viking Therapeutics (VKTX) reported a Q3 loss of $1.55 per share, missing estimates by $0.49, due to increased R&D spending. Shares fell 2.4% after-hours. The company advanced obesity drug trials and raised $575M in offerings, ending Q3 with $960M in cash.
How this was made
The 30-second read
Why it matters
Earnings miss and higher R&D spend create immediate downside risk, while trial data may support future upside.
Market read
The earnings miss and trial updates are material for traders with exposure to biotech equities.
What to watch
Cash runway of $960M and recent capital raise provide financial flexibility for upcoming trials.
Background
VKTX is a Nasdaq-listed biotech focused on obesity treatments, reporting its Q3 results and trial progress.
Ticker impact
VKTX reported a Q3 loss of $1.55 per share, missing estimates, and disclosed Phase 3 trial updates for VK2735.
likely pressure as the market prices in the earnings miss and increased expense guidance
The loss miss and rising expenses suggest near-term weakness, but the Phase 3 data could mitigate longer-term risk.
Market effects
Biotech sector may see modest pullback as earnings miss highlights spending pressures.
U.S. biotech stocks could face slight downside in early trading.
Limited; primarily affects U.S. listed biotech investors.
Counterpoint
Positive Phase 3 data could outweigh short-term earnings disappointment, offering a buying opportunity.
Key entities
- companyViking Therapeutics Inc
Biopharmaceutical company developing obesity drugs.
